ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX
Lineage Cell Therapeutics, Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	United States of America	LCTX
Lipigon Pharmaceuticals AB Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.	Sweden	LPGO
Lipocine Inc. Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.	United States of America	LPCN
Lipum AB Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.	Sweden	LIPUM
Liquidia Corp Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.	United States of America	LQDA
LISATA THERAPEUTICS, INC. Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.	United States of America	LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.	United States of America	LIXT
Longeveron Inc. Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.	United States of America	LGVN
Lonza Group AG A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.	Switzerland	LONN